Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial-Reference-Cited by-同舟云学术

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

Published:2020-02 Issue:2 Volume:82 Page:352-359
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Puig Luis,Lebwohl Mark,Bachelez Hervé,Sobell Jeffrey,Jacobson Abby A.

Funder

Ortho Dermatologics

Amgen

AbbVie

Janssen

Eli Lilly and Company

Novartis

Pfizer

Abbvie

Boehringer Ingelheim

Celgene

Lilly

Incyte

Johnson & Johnson

Leo

MedImmune

AstraZeneca

SciDerm

Valeant

Vidac

Publisher

Elsevier BV

Subject

Dermatology

Reference17 articles.

1. Biologic fatigue in psoriasis;Levin;J Dermatolog Treat,2014

2. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study;Kimball;J Eur Acad Dermatol Venereol,2013

3. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3);Blauvelt;J Am Acad Dermatol,2017

4. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study;Bissonnette;Br J Dermatol,2017

5. Clinical meaningfulness of complete skin clearance in psoriasis;Strober;J Am Acad Dermatol,2016

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer;BMJ Case Reports;2024-08

2. Brodalumab: 5-Year US Pharmacovigilance Report;Dermatology and Therapy;2024-05

3. Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort;Dermatology Practical & Conceptual;2024-04-30

4. Interleukin inhibitors and the associated risk of candidiasis;Frontiers in Immunology;2024-03-28

5. Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study);Journal of the European Academy of Dermatology and Venereology;2024-02-03